Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced Asthma
Phase of Trial: Phase II/III
Latest Information Update: 01 Jun 2016
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Torii Pharmaceutical
- 18 Aug 2015 According to an ALK-Abello media release, the New Drug Application submitted by its partner, Torii, to the Japanese Ministry of Health, Labour and Welfare has been accepted for review.
- 02 Sep 2014 Based on results of this trial and the second pivotal trial, Torii Pharmaceuticals is expected to submit a registration application in Japan within 6 months, according to an ALK-Abello media release.
- 16 Jun 2014 Primary endpoint 'Risk of moderate to severe asthma exacerbations' has not been met according to the ALK-Abello media release.